Contraindicated (one)bortezomib will enhance the stage or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may well improve mavacamten systemic exposure, resulting in coronary heart failure as a result of systolic dysfunction. levoketoconazole will raise the amount or impact of bortezomib by impacting https://assisiv221mzk5.blogaritma.com/profile